Molecular farming for sustainable production of clinical‐grade antimicrobial peptides

Abstract

SummaryAntimicrobial peptides (AMPs) are emerging as next‐generation therapeutics due to their broad‐spectrum activity against drug‐resistant bacterial strains and their ability to eradicate biofilms, modulate immune responses, exert anti‐inflammatory effects and improve disease management. They are produced through solid‐phase peptide synthesis or in bacterial or yeast cells. Molecular farming, i.e. the production of biologics in plants, offers a low‐cost, non‐toxic, scalable and simple alternative platform to produce AMPs at a sustainable cost. In this review, we discuss the advantages of molecular farming for producing clinical‐grade AMPs, advances in expression and purification systems and the cost advantage for industrial‐scale production. We further review how ‘green’ production is filling the sustainability gap, streamlining patent and regulatory approvals and enabling successful clinical translations that demonstrate the future potential of AMPs produced by molecular farming. Finally, we discuss the regulatory challenges that need to be addressed to fully realize the potential of molecular farming‐based AMP production for therapeutics.